Non-small cell lung cancer

News

AZ, Daiichi get Datroway nod in lung cancer on second try

AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.

News

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.

News

Summit shrugs off survival miss with its VEGF bispecific

Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.

News

MSD and Daiichi Sankyo pull HER3-DXd's FDA filing

MSD and Daiichi Sankyo suffer another setback with their HER3 programme ahead of a crucial data readout at ASCO.

News

AbbVie bags first approval for cancer ADC Emrelis

AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.

News

Dr Yu Xia, founder, chairwoman, president and chief executive of Akeso

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

AZ, Daiichi get Datroway nod in lung cancer on second try

FDA clears Nuvation's first product Ibtrozi, for lung cancer

Summit shrugs off survival miss with its VEGF bispecific

MSD and Daiichi Sankyo pull HER3-DXd's FDA filing

AbbVie bags first approval for cancer ADC Emrelis

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

LSX2026: On a therapeutic vision for ocular disease, with Al...

Using AI-driven synthetic personas to take your insights fur...

Non-small cell lung cancer

Editor's Picks